Literature DB >> 10694797

Glucose regulated production of human insulin in rat hepatocytes.

P M Thulé1, J Liu, L S Phillips.   

Abstract

Insulin gene therapy requires that insulin secretion be coupled to metabolic requirements. To this end, we have developed an insulin transgene whose transcription is stimulated by glucose and inhibited by insulin. Glucose- and insulin-sensitive promoters were constructed by inserting glucose-responsive elements (GlREs) from the rat L-pyruvate kinase (L-PK) gene into the insulin-sensitive, liver-specific, rat insulin-like growth factor binding protein-1 (IGFBP-1) promoter. Glucose (5 to 25 mM) stimulated, and insulin (10-10 to 10-7 M) inhibited, luciferase expression driven by these promoters in primary cultured rat hepatocytes. The capacity of transfected hepatocytes to secrete mature, biologically active insulin was demonstrated using a human proinsulin cDNA (2xfur), modified to allow protein processing by endogenous endopeptidase activity. Medium conditioned by insulin-producing hepatocytes contained greater than 300 microU/ml immunoreactive insulin, while denaturing SDS-PAGE of an anti-insulin immunoprecipitate revealed bands with the mobilities of insulin A, and B chains. Biological activity of hepatocyte-produced insulin was demonstrated in a transfection assay, in which medium conditioned by insulin-producing hepatocytes exerted an effect similar to 10-7 M insulin. We then combined the glucose- and insulin-sensitive promoter with the modified human proinsulin cDNA to create a metabolically sensitive insulin transgene ((GlRE)3BP-1 2xfur). In both H4IIE hepatoma cells stably transfected with this construct, and normal rat hepatocytes (GlRE)3BP-1 2xfur-mediated insulin secretion increased in response to stimulation by glucose. Moreover, a capacity to decrease insulin production in response to diminishing glucose exposure was also demonstrated. We conclude that the transcriptional regulation of insulin production using these glucose- and insulin-sensitive constructs meets the requirements for application in a rodent model of insulin gene therapy. Gene Therapy (2000) 7, 205-214.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694797     DOI: 10.1038/sj.gt.3301076

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  19 in total

1.  Therapeutic effects of a non-β cell bioartificial pancreas in diabetic mice.

Authors:  Aubrey R Tiernan; Peter M Thulé; Athanassios Sambanis
Journal:  Transplantation       Date:  2014-09-15       Impact factor: 4.939

2.  A cell-based approach for diabetes treatment using engineered non-beta cells.

Authors:  Heather Bara; Peter M Thulé; Athanassios Sambanis
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

3.  Protamine sulfate enhances the transduction efficiency of recombinant adeno-associated virus-mediated gene delivery.

Authors:  Y W Yang; Y C Hsieh
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

4.  Harnessing endogenous signals from hepatocytes using a low volume multi-well plate.

Authors:  Pantea Gheibi; Kyung Jin Son; Gulnaz Stybayeva; Alexander Revzin
Journal:  Integr Biol (Camb)       Date:  2017-05-22       Impact factor: 2.192

5.  Combinatorial insulin secretion dynamics of recombinant hepatic and enteroendocrine cells.

Authors:  Kiranmai Durvasula; Peter M Thulé; Athanassios Sambanis
Journal:  Biotechnol Bioeng       Date:  2011-11-21       Impact factor: 4.530

6.  Glucose- and metabolically regulated hepatic insulin gene therapy for diabetes.

Authors:  Paul Yueh-Jen Hsu; Robert M Kotin; Ya-Wun Yang
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

7.  Construction of a recombinant human insulin expression vector for mammary gland-specific expression in buffalo (Bubalus bubalis) mammary epithelial cell line.

Authors:  Ramakant Kaushik; Karn Pratap Singh; Archana Kumari; K Rameshbabu; Manoj Kumar Singh; Radhey Shyam Manik; Prabhat Palta; Suresh Kumar Singla; Manmohan Singh Chauhan
Journal:  Mol Biol Rep       Date:  2014-06-27       Impact factor: 2.316

8.  Engineered insulin secretion from neuroendocrine cells isolated from human thyroid.

Authors:  Peter M Thulé; Dingwu Jia; Susan Safley; Kereen Gordon; Graham Barber; Hong Yi; Soumya Nalli; Muhittin Onderci; Jyotirmay Sharma; John Shires; Collin J Weber
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

9.  Treatment of diabetes by transplantation of drug-inducible insulin-producing gut cells.

Authors:  Suraj Unniappan; Rhonda D Wideman; Christine Donald; Virginia Gunn; Jennifer L Wall; Qiu-Xia Zhang; Travis D Webber; Anthony T Cheung; Timothy J Kieffer
Journal:  J Mol Med (Berl)       Date:  2009-04-23       Impact factor: 4.599

10.  Glucose-modulated transgene expression via recombinant adeno-associated virus.

Authors:  Ya-Wun Yang; Yuan-Chiao Hsieh; Chih-Kai Chao
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.